Protara Therapeutics (TARA) announced the appointment of Leonardo Viana Nicacio as chief medical officer. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across biopharmaceutical and health technology companies. Nicacio most recently served as head of clinical development and global medical affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics’ TARA-002 Shows Promising Potential in NMIBC Treatment, Justifying Buy Rating
- Protara Therapeutics announces presentation of results from THRIVE-1 study
- Cantor starts Protara with Overweight, sees ‘multi-bagger potential’
- Protara Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Protara Therapeutics initiated with an Outperform at LifeSci Capital